This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Trovagene's Onvansertib Shows Response in Phase Ib AML Study
by Zacks Equity Research
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
by Zacks Equity Research
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Should Value Investors Buy Sanofi (SNY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
by Zacks Equity Research
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.
Emergent's Vaccine Portfolio Aids Growth Amid Competition
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
Inovio (INO) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Esperion's Drugs in Review Hold Potential, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Is Sanofi (SNY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
by Zacks Equity Research
Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.
Should Value Investors Consider Sanofi (SNY) Stock Now?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
by Zacks Equity Research
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.